TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER

• Main Authors: O''MALLEY Bert W, NIKOLAI Bryan, HAN Sang Jun, LONARD David M, JAIN Prashi, GILAD Yosef, DACSO Clifford
• Format: Patent
• Language: English; Spanish
• Published: 18.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration. La presente divulgación se refiere a métodos y composiciones relacionadas con el tratamiento del cáncer que comprenden el direccionamiento de SRC-3 en células inmunitarias, incluidas las células T tales como las células T reguladoras. El direccionamiento de SRC-3 en células T reguladoras en particular es efectivo para erradicar tumores en mamíferos. En casos específicos, las células T reguladoras se someten a CRISPR ex-vivo para producir células adecuadas para la transferencia celular adoptiva. En algunos casos, también se administran al individuo uno o más agentes que se dirigen a SRC-3 y/o se exponen a las células antes de la administración.